Topic
Psychotropic drug
About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, the effect of antidepressants on CRH gene promoter activity was investigated in undifferentiated and differentiated Neuro-2A cells, and for comparison the effect on selected antidepressants on AtT-20 cells.
33 citations
TL;DR: The efficacy of biannual structured medication reviews to improve the appropriateness of psychotropic drug prescriptions for neuropsychiatric symptoms in nursing home patients with dementia is studied.
Abstract: Objective: We studied the efficacy of biannual structured medication reviews to improve the appropriateness of psychotropic drug (PD) prescriptions for neuropsychiatric symptoms (NPS) in nursing home patients with dementia. Study Design and Setting: In this randomised controlled trial, the intervention encompassed a structured multidisciplinary medication review by physician, pharmacist and nurse. During this 18-month study, the patient's medical files were assessed every 6 months. The primary outcome was the appropriateness of PD prescriptions defined by the Appropriate Psychotropic drug use In Dementia (APID) index sum score, lower scores indicating more appropriate use. Results: At baseline, 380 patients were included, of which 222 were randomised to the intervention group. Compared to the control group, the APID index sum score in the intervention group improved significantly for all PD prescriptions (-5.28, P = 0.005). Conclusion: We advise the implementation of a structured, repeated medication review with the essential roles of pharmacist, physician and nurse, into daily practice. This work was supported and funded by the Netherlands Organisation for Health Research and Development (ZonMw). Netherlands Trial Register (NTR3569).
33 citations
Book•
01 Jan 1986
TL;DR: An evaluation of GABA- and neuropeptide-mediated influences in the visual cortex and inositude metabolism in the brain: its potential role in complex neuronal pathways.
Abstract: L L Iversen: Introduction AMINO ACIDS AS FAST SIGNALS: K Krnjevi 'c: Amino acid transmitters: 30 years' progress in research J L Barker, B Dufy & R N McBurney: Amino acid and peptide signals in cultured CNS neurons and clonal pituitary cells J S Kelly, V Crunelli, S Forda, N Leresche & M Pirchio: Fast synaptic responses in the hippocampus and dorsal lateral geniculate nucleus of the rat A M Sillito: Fast and slow chemical signalling in the visual cortex: an evaluation of GABA- and neuropeptide-mediated influences P Krogsgaard-Larsen, L Nielsen, U Madsen & E Nielsen: GABA and glutamic acid agonists of pharmacological interest J C Watkins: Selective antagonists define sub-classes of excitatory amino acid receptors S H Snyder: Multiple benzodiazepine and related receptors as targets for psychotropic drug action E H F Wong & J Kemp: Amino acids as fast signals: discussion NEUROPEPTIDES AND MONOAMINES AS SLOW SIGNALS: G N Woodruff: Receptors and second messengers for neuropeptides and monoamines D A Brown: Voltage-sensitive ion channels mediating modulatory effects of acetylcholine, amines, and peptides S I Walaas, J K-T Wang & P Greengard: First messengers, second messengers, and protein phosphorylation in CNS T M Jessell & C E Jahr: Synaptic interactions between dorsal root ganglion and dorsal horn neurons in cell culture: amino acids, nucleotides, and peptides as possible fast and slow excitatory transmitters R F Irvine & M J Berridge: Inositude metabolism in the brain: its potential role in complex neuronal pathways T H "okfelt et al: Coexistence of peptides and other active molecules in neurons: diversity of chemical signalling potential S Freedman & K Watling: Neuropeptides and monoamines as slow signals: discussion CHEMICALLY ADDRESSED NEURAL COMMUNICATIONS: F O Schmitt: Chemical information processing in the brain: prospect from retrospect E A Kravitz: Serotonin, octopamine, and proctolin: two amines and a peptide, and aspects of lobster behaviour W Sossin, T Kreiner & R H Scheller: Aplysia neurosecretory cells: multiple populations of dense core vesicles D E Koshland Jr: Molecular mechanisms for memory F E Bloom: Chemical signalling in the spatial, temporal continuum J D Salamone & N G Bowery: Chemically addressed neural communications: discussion Index.
33 citations
TL;DR: The recent history of somatic treatment of mental illness is reviewed and possible roles for social workers in the prescription of psychotropic drugs are discussed.
Abstract: This article reviews the recent history of somatic treatment of mental illness and discusses possible roles for social workers in the prescription of psychotropic drugs. Social work has neglected drug treatments partly because of the way social workers of an earlier era resolved doubts about the immediate predecessor of drugs, shock treatment. Today, the prevalence and misdiagnosis of treatment-induced adverse effects, the unique perspective of social work, the blurring of functions, and the interprofessional competition in mental health-as well as the goal of enhancing our clients' welfare-have removed practical and scientific obstacles to social work's serious and autonomous study of psychotropic drug treatments.
33 citations
TL;DR: Until better controlled studies evaluating both teratogenic effects and long-term toxic consequences of exposure to psychotropic drugs in utero or through breast milk are available, women who are pregnant or plan to become pregnant and nursing mothers must be individually evaluated.
Abstract: Treating psychiatrically ill female patients during pregnancy with psychotropic drugs presents the physician with many clinical dilemmas.1 The U.S. Food and Drug Administration (FDA) has not approved any psychotropic use during pregnancy though the use of these medications is common.2,3 Once considered a time of emotional well-being for women, a growing literature suggests that pregnancy may not convey the “protection” against psychiatric disorder once believed.4–7 The marked prevalence of psychiatric disorders during pregnancy and the growing evidence that psychiatric patients may be at high risk for relapse when medications are discontinued8–11 make treatment planning for psychiatrically ill pregnant women and for those who may wish to conceive much more difficult. Balancing the risk of fetal exposure with the risk of untreated psychiatric disorder places the clinician “between a teratologic rock and a clinical hard place.”12
33 citations